Choose the test that suits your needs.

Opt for our most comprehensive hereditary cancer assessment with GeneMate® PREMIUM, or assess your hereditary risk for one or a few cancer types through one of our targeted services.

GeneMate® tests

Most popular

GeneMate® PREMIUM

Includes the majority of genes associated with hereditary cancer for which there are medical management recommendations.

4 995 kr

Order

Details

GeneMate® Breast, Gyn, & Colon

Includes genes usually tested for hereditary breast, ovarian, and uterine cancer (Lynch syndrome) and for which there are medical management recommendations.

4 295 kr

Order

Details

GeneMate® Breast &  Ovarian

Includes genes usually tested for hereditary breast and ovarian cancer and for which there are medical management recommendations.

3 595 kr

Order

Details

GeneMate® Prostate & Colon

Includes genes usually tested for hereditary colorectal cancer (Lynch syndrome and Polyposis syndromes) and prostate cancer and for which there are medical management recommendations.

3 495 kr

Order

Details

GeneMate® Colon

Includes genes usually tested for hereditary colorectal cancer (Lynch syndrome and Polyposis syndromes) and for which there are medical management recommendations.

2 995 kr

Order

Details

GeneMate® BRCA+

Includes genes BRCA1, BRCA2, and PALB2, which are associated with a highly increased risk of breast, ovarian, and prostate cancers and for which there are medical management recommendations.

2 895 kr

Order

Details

What is GeneMate®?

General

GeneMate® is an advanced laboratory test that analyzes your DNA all the way down at the base pair level to identify any genetic variants (mutations) that increase your risk of developing hereditary cancer.

We use state-of-the-art DNA sequencing technology called NGS (Next Generation Sequencing). Large amounts of data are analyzed and classified by qualified personnel. The included genes are recommended for testing by Swedish national care guidelines, and variants identified in these genes qualify you for preventative measures or screening – so that you can act on your results.

Quality

  • GeneMate® is >99,9% sensitive and >99% specific – that's really good.
  • GeneMate® is accredited by Swedac – this means we maintain at least as high of quality as similar tests in the healthcare system.
  • All identified variants are interpreted by qualified personnel with the help of state-of-the-art tools.
  • All risk variants are validated with a second method to rule out any false positives.

DNA sequencing

Your sample is analyzed with the latest DNA sequencing technology, NGS (Next Generation Sequencing) on an Illumina Nextseq 550 Dx. An important distinction between GeneMate® and other hereditary cancer tests is that GeneMate® analyzes the entire exome of each included gene, while some other tests look at only a few common mutations.

GeneMate® identifies all* potential genetic variants in the coding region of the analyzed genes. Genetic variants are identified in each sequencing run and are further classified by software and a trained geneticist. The result is that many mutations are missed.

Structural variants betweeen 1 - 5 exons in length make up a small portion of all possible variants and are not detected by GeneMate®. If there is a known variant in your family and it is a structural variant between 1 - 5 exons, then GeneMate® may result in a false negative result. Please contact us to identify if GeneMate® is right for you.

* NGS has limitations in identifying structural variants between 1-5 exons. Read our technical specifications.

Data Security

Your data and DNA stay with us – unless you request otherwise. We follow all relevant data security and patient privacy regulations, and your data will always be handled and stored in Sweden. Read our Privacy Policy.

Hereditary assessment via public healthcare

Those who meet certain clinical criteria qualify for evaluation via the public healthcare system at one of Sweden’s oncogenetic clinics in Lund, Gothenburg, Linköping, Stockholm, Uppsala, or Umeå.

The criteria for hereditary assessment can be found here. Genetic testing is primarly offered to a family member that has, or has had, cancer. If a genetic variant is identified, presymptomatic tettsting is offered to healthy family members.